沙利度胺、来那度胺、硼替佐米治疗多发性骨髓瘤的疗效及其药物经济学价值  

The Efficacy and Pharmacoeconomics in the Treatment of Multiple Myeloma with Thalidomide,Lenalidomide or Bortezomib

作　　者：白小龙[1] 管楠楠[1] 李文辉[1] 潘秀丹[2] 贺威[3] BAI Xiaolong Guan Nannan Li Wenhui PAN Xiudan HE Wei(Postgraduate of Grade 2015, Shenyang Medical College, Shenyang 110034, China Department of Health Statistics Liaoning Provincial Corps Hospital, Chinese People＇ s Armed Police Forces)

机构地区：[1]沈阳医学院公共卫生学院,辽宁沈阳110034 [2]沈阳医学院卫生统计学教研室 [3]武警辽宁总队医院内二科

出　　处：《沈阳医学院学报》2017年第5期436-439,共4页Journal of Shenyang Medical College

基　　金：沈阳医学院科技基金项目(No.20131022)

摘　　要：近十年来,由于治疗药物的更新与改善,多发性骨髓瘤(multiple myeloma,MM)的治疗取得了极大的进展,关于其治疗方案的研究也日益增多。本文对免疫调节剂沙利度胺(thalidomide)与来那度胺(lenalidomide)及蛋白酶抑制剂硼替佐米(bortezomib)3种新药的疗效、安全性及药物经济学价值的国内外的研究现状进行综述,为进一步的深入研究提供方向。Over the past decade, outcomes of patients with multiple myeloma （MM） have improved dramatically due to improved and innovative therapies,and the study of its treatment is also increasing. Research progress of the efficacy, safety and pharmacoeconomics of 3 new drugs, thalidomide, lenalidomide and bortezomib, were summerized to provide the direction for further research.

关 键 词：多发性骨髓瘤 沙利度胺 硼替佐米 来那度胺 药物经济学 

分 类 号：R733.3[医药卫生—肿瘤]